These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7113961)

  • 1. Phase II trial of bruceantin in metastatic breast carcinoma.
    Wiseman CL; Yap HY; Bedikian AY; Bodey GP; Blumenschein GR
    Am J Clin Oncol; 1982 Aug; 5(4):389-91. PubMed ID: 7113961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma.
    Arseneau JC; Wolter JM; Kuperminc M; Ruckdeschel JC
    Invest New Drugs; 1983; 1(3):239-42. PubMed ID: 6678872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study on bruceantin administered on a weekly schedule.
    Liesmann J; Belt RJ; Haas CD; Hoogstraten B
    Cancer Treat Rep; 1981; 65(9-10):883-5. PubMed ID: 7273023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
    Amato DA; Borden EC; Shiraki M; Enterline HT; Rosenbaum C; Davis HL; Paul AR; Stevens CM; Lerner HJ
    Invest New Drugs; 1985; 3(4):397-401. PubMed ID: 2417985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial clinical studies with bruceantin.
    Bedikian AY; Valdivieso M; Bodey GP; Murphy WK; Freireich EJ
    Cancer Treat Rep; 1979; 63(11-12):1843-7. PubMed ID: 526918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of bruceantin by radioimmunoassay.
    Fong KL; Ho DH; Benjamin RS; Brown NS; Bedikian A; Yap BS; Wiseman CL; Kramer W; Bodey GP
    Cancer Chemother Pharmacol; 1982; 9(3):169-72. PubMed ID: 7160053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of bruceantin.
    Garnick MB; Blum RH; Canellos GP; Mayer RJ; Parker L; Skarin AT; Li FP; Henderson IC; Frei E
    Cancer Treat Rep; 1979; 63(11-12):1929-32. PubMed ID: 526926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunoassay for the detection and quantitation of bruceantin.
    Fong KL; Ho DH; Carter CJ; Brown NS; Benjamin RS; Freireich EJ; Bodey GP
    Anal Biochem; 1980 Jul; 105(2):281-6. PubMed ID: 7457834
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumor activity of novel ailanthone derivatives in vitro and in vivo.
    Kato T; Suzumura Y; Fukushima M; Honda T; Nakanishi T; Noguchi T
    Anticancer Res; 1988; 8(4):573-9. PubMed ID: 3178149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yadanzioside P, a new antileukemic quassinoid glycoside from Brucea javanica (L.) Merr with the 3-O-(beta-D-glucopyranosyl)bruceantin structure.
    Sakaki T; Yoshimura S; Tsuyuki T; Takahashi T; Honda T
    Chem Pharm Bull (Tokyo); 1986 Oct; 34(10):4447-50. PubMed ID: 3829175
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
    Rivera E; Holmes FA; Frye D; Valero V; Theriault RL; Booser D; Walters R; Buzdar AU; Dhingra K; Fraschini G; Hortobagyi GN
    Cancer; 2000 Dec; 89(11):2195-201. PubMed ID: 11147589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimalarial activity of bruceantin in vitro.
    Guru PY; Warhurst DC; Harris A; Phillipson JD
    Ann Trop Med Parasitol; 1983 Aug; 77(4):433-5. PubMed ID: 6357122
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of anguidine in advanced breast cancer.
    Yap HY; Murphy WK; DiStefano A; Blumenschein GR; Bodey GP
    Cancer Treat Rep; 1979 May; 63(5):789-91. PubMed ID: 455316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor agents XLII: Comparison of antileukemic activity of helenalin, brusatol, and bruceantin and their esters on different strains of P-388 lymphocytic leukemic cells.
    Hall IH; Lee KH; Okano M; Sims D; Ibuka T; Liou YF; Imakura Y
    J Pharm Sci; 1981 Oct; 70(10):1147-50. PubMed ID: 7299649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quassinoid bitter principles. II.
    Polonsky J
    Fortschr Chem Org Naturst; 1985; 47():221-64. PubMed ID: 3896993
    [No Abstract]   [Full Text] [Related]  

  • 16. 1H- and 13C-NMR spectroscopic studies of selected quassinoids.
    Hamburger MO; Cordell GA
    Planta Med; 1988 Aug; 54(4):352-5. PubMed ID: 3222379
    [No Abstract]   [Full Text] [Related]  

  • 17. Bruceantin, a potent amoebicide from a plant, Brucea antidysenterica.
    Gillin FD; Reiner DS; Suffness M
    Antimicrob Agents Chemother; 1982 Aug; 22(2):342-5. PubMed ID: 6100431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversibility of protein synthesis inhibition by quassinoid antineoplastic agents in a rabbit reticulocyte system.
    Willingham W; Considine RT; Chaney SG; Lee KH; Hall IH
    Biochem Pharmacol; 1984 Jan; 33(2):330-3. PubMed ID: 6704156
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience.
    Bruno S; Puerto VL; Mickiewicz E; Hegg R; Texeira LC; Gaitan L; Martinez L; Fernandez O; Otero J; Kesselring G
    Am J Clin Oncol; 1995 Oct; 18(5):392-6. PubMed ID: 7572754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.